OTCMKTS:AIMD Ainos (AIMD) Stock Price, News & Analysis $0.48 -0.05 (-9.83%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsBuy This Stock About Ainos Stock (OTCMKTS:AIMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ainos alerts:Sign Up Key Stats Today's Range$0.46▼$0.5450-Day Range$0.48▼$0.6452-Week Range$0.40▼$1.46Volume457,845 shsAverage Volume575,863 shsMarket Capitalization$7.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Read More… Receive AIMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ainos and its competitors with MarketBeat's FREE daily newsletter. Email Address AIMD Stock News HeadlinesAinos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart ManufacturingApril 30, 2025 | finance.yahoo.comAinos, Inc.: Ainos Reports Full Year 2024 Financial ResultsMarch 7, 2025 | finanznachrichten.deAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.May 22, 2025 | Paradigm Press (Ad)Ainos, Inc.: Ainos and ugo to Develop the World's First Robot With a Sense of SmellMarch 5, 2025 | finanznachrichten.deAinos, ugo to develop robot with sense of smellMarch 5, 2025 | markets.businessinsider.comAinos, Inc.: Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral InnovationJanuary 27, 2025 | finanznachrichten.deAinos, Inc.: Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled RobotsJanuary 14, 2025 | finanznachrichten.deAinos, Inc.: CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONADecember 18, 2024 | finanznachrichten.deSee More Headlines AIMD Stock Analysis - Frequently Asked Questions How have AIMD shares performed this year? Ainos' stock was trading at $0.4560 at the beginning of 2025. Since then, AIMD shares have increased by 4.6% and is now trading at $0.4770. View the best growth stocks for 2025 here. When did Ainos' stock split? Ainos shares reverse split on Tuesday, August 9th 2022. The 1-15 reverse split was announced on Tuesday, August 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Ainos? Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ainos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ainos investors own include CRISPR Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Vistagen Therapeutics (VTGN), Alpha Lithium (APHLF), Baidu (BIDU), DiDi Global (DIDIY) and Kingsoft Cloud (KC). Company Calendar Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:AIMD CIK1014763 Webwww.amarbio.com Phone(858) 869-2986Fax806-376-9301Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,010,000.00 Net Margins-515.80% Pretax Margin-515.76% Return on Equity-44.32% Return on Assets-40.35% Debt Debt-to-Equity Ratio0.08 Current Ratio1.92 Quick Ratio1.45 Sales & Book Value Annual Sales$106,207.00 Price / Sales69.31 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.32Miscellaneous Outstanding Shares15,433,000Free Float13,322,000Market Cap$7.36 million OptionableNot Optionable Beta2.14 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:AIMD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.